Luan Nguyen

Independent Insight Provider

Equity Bottom-Up

<p>This is the part II of collaboration on <a href="https://www.smartkarma.com/entities/3sbio-inc" target="_blank" data-smartkarma-citation="entities:459:1">3SBio Inc (1530 HK)</a> between <a href="https://www.smartkarma.com/profiles/950" target="_blank" data-smartkarma-citation="accounts:950">Dr. Bhavneesh Sharma, MD, MBA</a> and <a href="https://www.smartkarma.com/profiles/960" target="_blank" data-smartkarma-citation="accounts:960">Luan Nguyen</a></p><h2><strong>DCF analysis</strong></h2><p>We have performed a DCF valuation and given the revenue drivers and R&amp;D pipeline provided by Dr. Bhavneesh Sharma, MD, MBA in part 1, we think the upside potential of this company is 40% from current level. The assumptions that result in an upside of 40% are:</p><p>- 73% growth in 2016, 26% growth in 2017, 15.3% growth in 2018, then 10% p.a. from 2019 to 2025 and 3% p.a. until…</p>

This is the part II of collaboration on 3SBio Inc (1530 HK) between Dr. Bhavneesh Sharma, MD, MBA and Luan NguyenDCF analysisWe have performed a DCF valuation and given the revenue drivers and R&amp;D pipeline provided by Dr. Bhavneesh Sharma, MD, MBA in part 1, we think the upside potential of this company is 40% from current level. The assumptions that result in an upside of 40% are:- 73% growth in 2016, 26% growth in 2017, 15.3% growth in 2018, then 10% p.a. from 2019 to 2025 and 3% p.a. until…

3SBio: A Leading, Pure-Play Chinese (HK-Listed) Biotechnology Company (Part II)